Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.…
A $52 Billion Fund Bought These 3 Stocks
Tango Therapeutics (NASDAQ: TNGX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 137 employees.
The shares were at 21.73 USD on 20 November 2026, up 171.3% over 52 weeks. Its 52-week range is 7.370 USD to 34.39 USD: the price is 36.8% below the high and 194.8% above the low.
Its market capitalisation is 3.68B USD.
Tango Therapeutics reports return on equity of -29.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 946.32M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 47.00 USD is 116.3% above the current price. The next earnings report is expected on 4 March 2027.